Collaboration Expanded to Accelerate Progress in MASH Diagnosis
Echosens and Boehringer Ingelheim have expanded their partnership to improve early detection, diagnosis, and care access for MASH.
Read MorePosted by Chris Wolski | Jun 11, 2025 | Unknown Origin & Other Cancer Types |
Echosens and Boehringer Ingelheim have expanded their partnership to improve early detection, diagnosis, and care access for MASH.
Read MorePosted by Chris Wolski | Mar 19, 2025 | Cardiovascular |
Researchers have successfully adapted high-field NMR-based lipoprotein analysis to cost-effective benchtop NMR systems.
Read MorePosted by Chris Wolski | Mar 7, 2025 | Diabetes & Metabolic Diseases |
A study highlights that premature menopause significantly increases the risk of Type 2 diabetes, emphasizing the need for early detection.
Read MorePosted by Chris Wolski | Feb 6, 2025 | Urinalysis & Toxicology |
Higher PVSA compliance rates lead to better clinical outcomes, enhancing the laboratory’s reputation and value to healthcare providers.
Read MorePosted by Andy Lundin | Jan 30, 2025 | Womens Health |
The Mirvie RNA platform identified a unique molecular signature predictive of severe fetal growth restriction, allowing early detection.
Read More